System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Asger Lund is an expert in Endocrinology at Gentofte Hospital (Denmark). As of October 2026, ScienceLeadR ranks Asger Lund in the top 1% of experts worldwide for Overnutrition, Overweight and Nutrition Disorders. Asger Lund has authored 115 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 14 of them ongoing. SLR score: 715 (community average: 125). How the SLR is computed.

LeadR Profile

Asger Lund Gentofte Hospital Denmark
715 ScienceLeadR Reputation 715

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Gastroenterology - Biochemistry - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2025
Source: PubMed

Copenhagen University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 115

Citations

Citations: 2 761 1st author: 9 Last author: 9 Unique author: 1

Main journals

Diabetes 33
Diabetes Obes Metab 11
J Clin Endocrinol Metab 8
Diabetologia 5
Eur J Endocrinol 5

Best Journals

Lancet Diabetes Endocrinol 2
Eur Heart J 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Short term overfeeding disrupts small intestinal barrier integrity and activates hepatic immunity in healthy men.
PMID 42866259 — cells, vascular cell adhesion molecule-1, tissue adhesions, life style, immunity, mucous membrane, plasma		iScience20260
Additive Glucagonotropic and Insulinotropic Effects of Glucose-Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men.
PMID 42712058 — fasting, alanine, insulin, amino acids, insulin secretion, hormones, glucagon, plasma		Diabetes Obes Metab20260
Intravenous Oxytocin Does Not Affect Glucose-Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men.
PMID 42687772 — glucagon-like peptide 1, bone remodeling, collagen, insulin secretion, hormones, oxytocin, glucagon, triglycerides, plasma		Diabetes Obes Metab20260
BASTA trial: protocol for a randomised, double-blind, placebo-controlled, crossover trial investigating the effects of atorvastatin on bile acid diarrhoea.
PMID 42521312 — clinical protocols, bile, signs and symptoms, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, atorvastatin		BMJ Open20260
Circulating levels of PYY are increased in individuals with bile acid diarrhoea.
PMID 42496159 — glucagon-like peptide 1, intestines, bile, fasting, colon, liraglutide, therapeutics, plasma		J Clin Endocrinol Metab20260

Clinical Studies 34

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

N/A 16
Phase 2 8
Phase 3 6
Phase 4 2
Phase 1 1
Phase 3/Phase 4 1

By status:

Completed 18
Active not recruiting 8
Recruiting 6
Unknown 2

By type:

Interventional 31
Observational 3

By Monocentric/Multicentric:

monocentric 27
multicentric2to4 1
multicentric5to9 0
multicentricup10 6

Main Topics

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Research study on how well oral semaglutide works for weight loss in adults with excess body weight
2025-524626-18-00 — safety, body weight, obesity, research, weight loss, overweight, semaglutide		Phase 3Recruiting2026
A research study to see how well CagriSema helps people with excess body weight lose weight
2023-506929-11-00 — safety, body weight, obesity, research, overweight, semaglutide		Phase 3Active not recruiting2022
Treatment of Bile Acid Diarrhoea with Atorvastatin (BASTA)
2025-521856-47-00 — bile, therapeutics, atorvastatin		Phase 3/Phase 4Recruiting2025
AMAZE 1 A research study investigating how well the medicine NNC0487 0111 helps people with excess body weight lose weight
2024-520440-42-00 — safety, body weight, obesity, research		Phase 3Recruiting2026
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME 1)
2024-515524-36-00 — diabetes mellitus, safety, obesity, therapeutics, overweight, diabetes mellitus, type 2, weight control		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS